InvestorsHub Logo

MarketProphet

10/13/17 11:03 AM

#3741 RE: Viky #3740

420 just tweeted this out 5 min's ago, great to get more exposure on the company. $ISOLF

Isodiol International Issues Corporate Update





2 min 32 sec ago
Isodiol International Inc.(CSE:ISOL) (OTC: $ISOLF ), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and nutraceutical products, announces fiscal 2018 Q2 revenues of its wholly owned subsidiary ISO International LLC of, $4.07 million USD ($5.1 million CDN) compared to fiscal 2018 Q1 revenues of $3.92 million USD ($4.92 million CDN).

Isodiol International CEO, Marcos Agramont stated, “Over the last quarter, we have expanded our footprint in Brazil and more recently our operations into Chile. We will continue to push our international expansion strategy by developing the European and Asian markets for our consumer products while working with local health authorities for medical approval of our flagship product, Isoderm. We had another strong quarter of revenue growth and will continue our commitment to delivering high-quality hemp-derived CBD products through innovative delivery methods, which is the core of our success.”

For more information on Isodiol, please visit www.isodiol.com

About Isodiol International Inc.

Isodiol International Inc. is the market leader in pharmaceutical and nutraceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.

Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.

Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.